The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2021 | Treating CRC with regorafenib in Latin America
Juan Manuel O’Connor, MD, Institute Alexander Fleming, Buenos Aires, Argentina, discusses optimizing regorafenib dosing in colorectal cancer from a Latin American perspective. Many advances in first- and second- line treatments, as well as reatments for refractory colorectal cancer have been made in recent years. Data from the randomized, phase II ReDOS trial (NCT02368886) has demonstrated that a lower dose of regorafenib, a receptor tyrosine kinase (RTK) inhibitor was well tolerated in patients. This interview took place at the ESMO World Congress on Gastrointestinal Cancer 2021.
